Bone
Biologics Corporation


 


August 11,
2015


 


	To:	Musculoskeletal
    Transplant Foundation (“MTF”)


 


	Re:	Side
    Letter Agreement (the “Agreement”) 


 





1.
Reference is made herein to the Letter Agreement, dated September 7, 2014 (the “Letter Agreement”), by and among
Bone Biologics Corporation (formerly known as Bone Biologics, Inc., “the “Company”), MTF and AFH. Terms
used but not defined herein have the meaning set forth in the Letter Agreement. Pursuant to the Letter Agreement, MTF is to
receive restricted shares of the Company equal to and not to exceed 2.5% of the fully diluted shares of the Company at the
time of the completion of the Milestone Targets. Notwithstanding that all of the Milestone Targets have not been reached, and
in consideration for the support and cooperation of MTF in trying to reach the Milestone Targets and the closing of certain
financings, including the conversion of debt by MTF in order to facilitate certain financings, the Company hereby authorizes
the issuance of Company shares to MTF in the amount of 2.5% of the fully diluted shares of the Company, Eight Hundred Sixty
Seven Thousand One Hundred Sixty-Three (867,163) shares.


 


2.
This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware without giving effect to
the conflicts of laws principles thereof. Each party hereby irrevocably and unconditionally consents to submit to the exclusive
jurisdiction of the courts of the State of Delaware and of the United States of America located in the State of Delaware for any
disputes, controversies, or claims arising out of or relating to this Agreement and the transactions contemplated hereby. The
parties hereby irrevocably waive any objection to jurisdiction and venue for any action instituted hereunder and shall not assert
any defense based on lack of jurisdiction or venue or based upon forum non conveniens. The parties agree to submit to the in personam
jurisdiction of such courts. The prevailing party in any such dispute shall be entitled to recover from the other party its reasonable
attorneys’ fees, costs and expenses. 


 


3.
This Agreement may be signed in two or more counterparts, each of which shall constitute an original, and all of which together
shall constitute one and the same agreement. The exchange of copies of this Agreement and of signature pages by facsimile transmission
or by email transmission in portable digital format, or similar format, shall constitute effective execution and delivery of such
instrument(s) as to the parties and may be used in lieu of the original for all purposes. Signatures of the parties transmitted
by facsimile or by email transmission in portable digital format, or similar format, shall be deemed to be their original signatures.



 


4. This Agreement and the Letter Agreement constitute the complete and entire agreement between the parties pertaining to the subject matter contained herein and supersedes all prior and contemporaneous discussions, negotiations, understandings, agreements, representations, and understandings of the Parties, whether oral or written, expressed or implied. Each of the Parties acknowledge that no other party, nor any agent or attorney of any other party, has made any promise, representation, or warranty whatsoever, express or implied, and not contained herein, concerning the subject matter hereof to induce the party to execute or authorize the execution of this Agreement, and acknowledges that the party has not executed or authorized the execution of this instrument in reliance upon any such promise, representation, or warranty not contained herein.








 






    	 



    	 	 	 



    

 


Very truly
yours,


 


	BONE
    BIOLOGICS CORPORATION	 
	 	 
	By:	/s/
    Michael Schuler	 
	Name:	Michael Schuler	 
	Title:	Chief Executive
    Officer	 


 


	Accepted
and Agreed to:


	 
	 	 
	THE
MUSCULOSKELETAL TRANSPLANT FOUNDATION


	 
	 	 
	By: 	/s/
    Michael     Kawas	 
	Name: 	Michael Kawas	 
	Title: 	Chief Financial
    Officer